Transgene SA (EPA: TNG)
1.130
+0.010 (0.89%)
Aug 30, 2024, 5:35 PM CET
Transgene Revenue
Transgene had revenue of 9.50M EUR in the half year ending June 30, 2024, with 374.91% growth. This brings the company's revenue in the last twelve months to 19.64M, down -20.70% year-over-year. In the year 2023, Transgene had annual revenue of 9.19M, down -64.26%.
Revenue (ttm)
19.64M
Revenue Growth
-20.70%
P/S Ratio
14.39
Revenue / Employee
56.03K
Employees
141
Market Cap
149.15M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTransgene News
- 1 year ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 1 year ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 1 year ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 1 year ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 1 year ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 2 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire
- 2 years ago - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 - Business Wire